Lorraine L. Lipscombe, MD, MSc
GIM/FP/GP:
Cardiology:
Endocrinology:
Lipscombe LL. In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes. Ann Intern Med. 2019;171:JC27. doi: https://doi.org/10.7326/ACPJ201909170-027
Download citation file:
© 2019
Published: Ann Intern Med. 2019;171(6):JC27.
DOI: 10.7326/ACPJ201909170-027
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by: